Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 52 Show results per page	View Search Criteria \| Help With Results


1.		Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				18 to 70				Other				2006-003750-23 LINFOTARGAM, NCT00466258


2.		Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 to 60				Other				AMLSG07-04 NCT00151242

Last Modified: 4/29/2008 First Published: 11/1/2002


3.		Phase III Randomized Study of Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone (BEACOPP) Versus Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) in Patients With Stage III or IV Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				16 to 60				Other				EORTC-20012 GELA-EORTC-20012, BNLI-EORTC-20012, GELCAB-EORTC-20012, NORDICLG-EORTC-20012, CAN-NCIC-EORTC-20012, ALLG-HD04, NCT00049595

Last Modified: 4/29/2008 First Published: 5/23/2003


4.		Phase III Randomized Study of Doxorubicin With Versus Without Ifosfamide and Pegfilgrastim in Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 60				Other				EORTC-62012 NCT00061984

Last Modified: 10/17/2008 First Published: 9/24/2003


5.		Phase III Randomized Study of Four Schedules of Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Patients With Node-Positive or High-Risk Node-Negative Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				SWOG-S0221 S0221, NCT00070564

Last Modified: 5/1/2008 First Published: 3/3/2006


6.		Phase III Randomized Study of Two Schedules of Adjuvant Chemotherapy Comprising Epirubicin, Cyclophosphamide, Methotrexate, and Fluorouracil Versus Two Schedules of Adjuvant Chemotherapy Comprising Epirubicin and Capecitabine in Patients With Completely Resected Early Stage Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Over 18				Other				ICR-TACT2 EU-205114, EUDRACT-2004-000066-13, MREC-04/MRE00/88, ISRCTN68068041, NCT00301925

Last Modified: 10/17/2008 First Published: 3/13/2006


7.		Phase III Study of Neoadjuvant and Adjuvant Cisplatin-Based Chemotherapy and/or Surgical Resection in Young Patients With Stage I-IV Adrenocortical Tumor

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Under 22 at diagnosis				NCI				COG-ARAR0332 ARAR0332, NCT00304070


8.		Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 60				Other				IIL-DLCL04 EudraCT number 2007-000275-42, NCT00499018

Last Modified: 9/17/2007 First Published: 8/10/2007


9.		Phase III Randomized Pilot Study of Adjuvant Chemotherapy Comprising Doxorubicin Hydrochloride or Epirubicin Hydrochloride and Cyclophosphamide in Older Women With Invasive Breast Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Biomarker/Laboratory analysis, Treatment				Active				70 and over				Other				UKM-CCH-ACTION ICR-CTSU/2006/10004-ACTION, EU-20751, EUDRACT-2005-005721, ISRCTN41708421, BIG-205, BIG 2-05, NCT00516425


10.		Various G-CSF Regimens to Prevent Infection During Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Approved-not yet active				18 and over				Other				2-2-6 STUDY ZonMw ID 80-82310-98-08006, EudraCT number 2007-005402-53, NCT00536081

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute